What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
Pharma & Biotech
AstraZeneca’s Imfinzi becomes first NHS immunotherapy for operable stomach cancer
Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.
Pharma & Biotech
What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Pharma & Biotech
What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy
Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.
Pharma & Biotech
Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Pharma & Biotech
What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering
Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.
Pharma & Biotech
Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes
FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.
Pharma & Biotech
Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.
Pharma & Biotech
Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.
Pharma & Biotech
How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
Janux Therapeutics advances JANX014 into Phase 1 for prostate cancer. Discover what this means for PSMA therapies and T cell engager safety.